Cymabay Therapeutics Inc

NASDAQ:CBAY  
3.95
+0.01 (+0.25%)
7:56:22 PM EDT: $4.03 +0.08 (+2.03%)
Earnings Announcements

CymaBay Reports Third Quarter And Nine Months Ended Sept 30 Financial Results

Published: 11/14/2022 21:47 GMT
Cymabay Therapeutics Inc (CBAY) - Cymabay Reports Third Quarter and Nine Months Ended September 30, 2022 Financial Results and Provides Corporate Update.
Qtrly Loss per Share $0.28.
Held $153.4 Million in Cash, Cash Equivalents and Investments As of September 30, 2022.
Cash and Investments on Hand Are Sufficient to Fund Cymabay's Operating Plan Through 2023.
Q3 Earnings per Share View $-0.30 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $6 Million
Adjusted EPS is expected to be -$0.26

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.31

More details on our Analysts Page.